Pembrolizumab - Pleural mesothelioma
You are here : Home > Formulary Search > Pembrolizumab - Pleural mesothelioma
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
See narrative
Formulations :
- Intravenous infusion
Formulary Status :
Associated Icons :
NFD2
SPC
Restrictions / Comments :
Important
This drug has not been assessed for formulary status.
NICE is unable to make a recommendation because the company has not provided an evidence submission. As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their formulary team to discuss possible alternatives/options
PAD Profile
ChemicalSubstance :
Pembrolizumab
Indication :
Pleural mesothelioma
Group Name :
Keywords :
Chemotherapy, lung cancer
Brand Names Include :
Keytruda
Important Information :
Latest Additions Date From :
04 Feb 2026
Latest Additions Date To :
04 Mar 2026
Guidelines :
Supporting Documents :
1
Committee Recommendations (0)
- No records returned.
Other Indications
Below are listed other indications that Pembrolizumab is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat Pleural mesothelioma.
- No records returned.